Delcath Systems (NASDAQ:DCTH – Get Free Report) is expected to issue its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Delcath Systems to post earnings of ($0.10) per share and revenue of $25.99 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.
Delcath Systems (NASDAQ:DCTH – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.16. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. The business had revenue of $29.13 million during the quarter, compared to the consensus estimate of $26.25 million. On average, analysts expect Delcath Systems to post ($0.17) EPS for the current fiscal year and $0.12 EPS for the next fiscal year.
Delcath Systems Price Performance
NASDAQ DCTH opened at $14.93 on Friday. The company has a market capitalization of $518.07 million, a price-to-earnings ratio of 1,494.49 and a beta of 0.62. The company’s fifty day moving average price is $15.45 and its two-hundred day moving average price is $12.44. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $17.42.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on DCTH
About Delcath Systems
Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.
Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.
Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.
See Also
- Five stocks we like better than Delcath Systems
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
